Market
Edwards lifts FY26 growth outlook following steady Q2 performance
Edwards Lifesciences raised its full-year 2026 revenue growth guidance following solid second-quarter results, driven primarily by its transcatheter aortic valve replacement (TAVR) business, which generated $1.26 billion in Q2 revenues. The company's strong TAVR performance underpinned confidence in its revised outlook.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network